Cart
sales@molnova.com
PDE5-IN-9
CAS No. 157862-84-5
PDE5-IN-9( —— )
Catalog No. M36099 CAS No. 157862-84-5
PDE5-IN-9 inhibits Phosphodiesterase PDE1c and is used to treat hypertension, heart failure, myocardial infarction, kidney failure, asthma, bronchitis, and dementia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | Get Quote |
|
| 10MG | 68 | Get Quote |
|
| 25MG | 109 | Get Quote |
|
| 50MG | 162 | Get Quote |
|
| 100MG | 236 | Get Quote |
|
| 500MG | 578 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePDE5-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDE5-IN-9 inhibits Phosphodiesterase PDE1c and is used to treat hypertension, heart failure, myocardial infarction, kidney failure, asthma, bronchitis, and dementia.
-
DescriptionPDE5-IN-9 (Compound 59) is a PDE5 inhibitor (IC50: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number157862-84-5
-
Formula Weight318.4
-
Molecular FormulaC18H14N4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(CC1=CC=CS1)C=2C3=C(N=C(N2)C=4C=CC=NC4)C=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sarvesh Paliwal, et al. Pharmacophore and molecular docking based identification of novel structurally diverse PDE-5 inhibitors. Medicinal Chemistry Research. 2015, 24, 576-587.
molnova catalog
related products
-
Lodenafil
Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
-
Carbazeran
Carbazeran is an inhibitor of PDE2 and PDE3 and can be used for studies about metabolic diseases. Carbazeran shows inotropic and chronotropic effects in vivo(EC50 = 100 μM).
-
Dovramilast
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor that reduces the production of pro-inflammatory mediators and cytokines.
